STOCK TITAN

[Form 4] QUEST DIAGNOSTICS INC Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Quest Diagnostics (DGX) reported an insider transaction by its SVP for Diagnostic Services. On 10/21/2025, the officer acquired 46 shares of common stock at $189.079, as noted in a footnote describing purchases via a dividend reinvestment plan eligible for deferred reporting under Rule 16a-6 but reported early. Following this, direct beneficial ownership stood at 15,333 shares.

Quest Diagnostics (DGX) ha riportato una transazione interna da parte del suo SVP dei Servizi Diagnostici. Il 21/10/2025 il dirigente ha acquisito 46 azioni ordinarie a 189,079 dollari ciascuna, come riportato in una nota a piè di pagina che descriveva acquisti tramite un piano di reinvestimento dei dividendi idoneo alla rendicontazione differita ai sensi della Regola 16a-6 ma segnalato in anticipo. A seguito di ciò, la proprietà diretta beneficiaria ammontava a 15.333 azioni.

Quest Diagnostics (DGX) informó una transacción de insider por su SVP de Servicios Diagnósticos. El 21/10/2025, el directivo adquirió 46 acciones comunes a 189,079 dólares, como se indica en una nota al pie que describe compras a través de un plan de reinversión de dividendos elegible para informes diferidos conforme a la Regla 16a-6, pero reportadas con anticipación. Tras esto, la titularidad directa beneficiosa se situó en 15,333 acciones.

퀘스트 다이노스틱스(DGX)는 진단 서비스 부문 수석 부사장의 내부자 거래를 보고했습니다. 2025년 10월 21일, 직원은 주당 189.079달러에 보통주 46주를 취득했으며, 이는 16a-6 규칙에 따라 연기된 보고가 가능한 배당 재투자 계획을 통해 매입을 설명하는 각주에 기재되었으나 조기에 보고되었습니다. 이로 인해 직접 실질 지분은 15,333주로 나타났습니다.

Quest Diagnostics (DGX) a signalé une transaction d'initié par son SVP des Services Diagnostiques. Le 21/10/2025, le responsable a acquis 46 actions ordinaires à 189,079 dollars chacune, comme indiqué dans une note de bas de page décrivant des achats via un plan de réinvestissement des dividendes éligible à un reporting différé en vertu de la règle 16a-6 mais rapporté en avance. Suite à cela, la propriété bénéficiaire directe s'élevait à 15.333 actions.

Quest Diagnostics (DGX) meldete eine Insider-Transaktion seines SVP für Diagnostische Dienstleistungen. Am 21.10.2025 erwarb der Beauftragte 46 Stammaktien zu je 189,079 US-Dollar, wie in einer Fußnote beschrieben, die Käufe über einen Dividendensparplan beschreibt, der für eine deferred reporting nach Regel 16a-6 berechtigt ist, jedoch vorzeitig gemeldet wurde. Danach belief sich das direkte wirtschaftliche Eigentum auf 15.333 Aktien.

Quest Diagnostics (DGX) أبلغت عن صفقة داخلية من قبل نائب رئيسها الأول للخدمات التشخيصية. في 21/10/2025، اشترى الموظف 46 سهما من الأسهم العادية بسعر 189.079 دولارا، كما ورد في هامش يصف عمليات شراء من خلال خطة إعادة استثمار الأرباح المؤهلة للتقارير المؤجلة وفق القاعدة 16a-6 لكن تم الإبلاغ عنها مبكرا. عقب ذلك، بلغت الملكية الفعالة المباشرة 15,333 سهما.

Positive
  • None.
Negative
  • None.

Quest Diagnostics (DGX) ha riportato una transazione interna da parte del suo SVP dei Servizi Diagnostici. Il 21/10/2025 il dirigente ha acquisito 46 azioni ordinarie a 189,079 dollari ciascuna, come riportato in una nota a piè di pagina che descriveva acquisti tramite un piano di reinvestimento dei dividendi idoneo alla rendicontazione differita ai sensi della Regola 16a-6 ma segnalato in anticipo. A seguito di ciò, la proprietà diretta beneficiaria ammontava a 15.333 azioni.

Quest Diagnostics (DGX) informó una transacción de insider por su SVP de Servicios Diagnósticos. El 21/10/2025, el directivo adquirió 46 acciones comunes a 189,079 dólares, como se indica en una nota al pie que describe compras a través de un plan de reinversión de dividendos elegible para informes diferidos conforme a la Regla 16a-6, pero reportadas con anticipación. Tras esto, la titularidad directa beneficiosa se situó en 15,333 acciones.

퀘스트 다이노스틱스(DGX)는 진단 서비스 부문 수석 부사장의 내부자 거래를 보고했습니다. 2025년 10월 21일, 직원은 주당 189.079달러에 보통주 46주를 취득했으며, 이는 16a-6 규칙에 따라 연기된 보고가 가능한 배당 재투자 계획을 통해 매입을 설명하는 각주에 기재되었으나 조기에 보고되었습니다. 이로 인해 직접 실질 지분은 15,333주로 나타났습니다.

Quest Diagnostics (DGX) a signalé une transaction d'initié par son SVP des Services Diagnostiques. Le 21/10/2025, le responsable a acquis 46 actions ordinaires à 189,079 dollars chacune, comme indiqué dans une note de bas de page décrivant des achats via un plan de réinvestissement des dividendes éligible à un reporting différé en vertu de la règle 16a-6 mais rapporté en avance. Suite à cela, la propriété bénéficiaire directe s'élevait à 15.333 actions.

Quest Diagnostics (DGX) meldete eine Insider-Transaktion seines SVP für Diagnostische Dienstleistungen. Am 21.10.2025 erwarb der Beauftragte 46 Stammaktien zu je 189,079 US-Dollar, wie in einer Fußnote beschrieben, die Käufe über einen Dividendensparplan beschreibt, der für eine deferred reporting nach Regel 16a-6 berechtigt ist, jedoch vorzeitig gemeldet wurde. Danach belief sich das direkte wirtschaftliche Eigentum auf 15.333 Aktien.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Plewman Patrick

(Last) (First) (Middle)
500 PLAZA DRIVE
C/O QUEST DIAGNOSTICS INC

(Street)
SECAUCUS NJ 07094

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
QUEST DIAGNOSTICS INC [ DGX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP for Diagnostic Services
3. Date of Earliest Transaction (Month/Day/Year)
10/21/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/21/2025 A V 46(1) A $189.079 15,333(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.
2. The amount includes exempt purchases made under the Company's stock purchase plan since the date of the last filing on Form 4.
Remarks:
Sean D. Mersten, Attorney in Fact for Patrick Plewman 10/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did DGX report on Form 4?

An SVP for Diagnostic Services acquired 46 common shares on 10/21/2025 at $189.079 per share.

What is the DGX insider’s total direct holdings after the transaction?

Direct beneficial ownership is 15,333 shares following the reported transaction.

How were the DGX shares acquired?

A footnote states the shares were acquired via a dividend reinvestment plan eligible for deferred reporting under Rule 16a-6, but reported early.

What is the insider’s role at Quest Diagnostics (DGX)?

The reporting person is an Officer, serving as SVP for Diagnostic Services.

What ownership form is indicated for the DGX shares?

The filing lists Direct (D) ownership of the reported holdings.

Does the filing mention other share purchases?

A footnote says the amount includes exempt purchases made under the Company’s stock purchase plan since the last filing.
Quest Diagnostics Inc

NYSE:DGX

DGX Rankings

DGX Latest News

DGX Latest SEC Filings

DGX Stock Data

20.38B
110.74M
0.4%
99.16%
3.8%
Diagnostics & Research
Services-medical Laboratories
Link
United States
SECAUCUS